$VTGN 👀 🔹️ Vistagen received the FDA's "Study May Proceed" letter for refisolone (its non-hormonal treatment for menopausal hot flashes) on April 22. 🔹️ Many

$VTGN 👀 🔹️ Vistagen received the FDA's "Study May Proceed" letter for refisolone (its non-hormonal treatment for menopausal hot flashes) on April 22. 🔹️ Many investors are watching July 21, approximately 90 days later, for a potential update regarding the company's negotiations with Fuji Pharma. …